Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Basic) (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EPS (Basic) for 16 consecutive years, with $0.02 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 100.59% to $0.02 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.76, a 80.16% increase, with the full-year FY2025 number at -$0.76, up 80.16% from a year prior.
  • EPS (Basic) was $0.02 for Q4 2025 at Anika Therapeutics, up from -$0.22 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.11 in Q4 2023 to a low of -$3.41 in Q4 2024.
  • A 5-year average of -$0.22 and a median of -$0.2 in 2022 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 307.5% in 2022; the steepest drop was 825.0% in 2022.
  • Anika Therapeutics' EPS (Basic) stood at -$0.4 in 2021, then skyrocketed by 307.5% to $0.83 in 2022, then skyrocketed by 33.73% to $1.11 in 2023, then crashed by 407.21% to -$3.41 in 2024, then soared by 100.59% to $0.02 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's EPS (Basic) are $0.02 (Q4 2025), -$0.22 (Q3 2025), and -$0.28 (Q2 2025).